Annual Accounts Receivable
$260.52 M
+$150.56 M+136.92%
December 31, 2023
Summary
- As of February 7, 2025, CHRS annual accounts receivable is $260.52 million, with the most recent change of +$150.56 million (+136.92%) on December 31, 2023.
- During the last 3 years, CHRS annual accounts receivable has risen by +$103.48 million (+65.89%).
- CHRS annual accounts receivable is now at all-time high.
Performance
CHRS Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$167.56 M
-$7.69 M-4.39%
September 30, 2024
Summary
- As of February 7, 2025, CHRS quarterly accounts receivable is $167.56 million, with the most recent change of -$7.69 million (-4.39%) on September 30, 2024.
- Over the past year, CHRS quarterly accounts receivable has dropped by -$48.95 million (-22.61%).
- CHRS quarterly accounts receivable is now -41.03% below its all-time high of $284.14 million, reached on March 31, 2024.
Performance
CHRS Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
CHRS Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +136.9% | -22.6% |
| 3 y3 years | +65.9% | +18.6% |
| 5 y5 years | +100.0% | +18.6% |
CHRS Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +136.9% | -41.0% | +83.8% |
| 5 y | 5-year | at high | +136.9% | -41.0% | +83.8% |
| alltime | all time | at high | -100.0% | -41.0% | -100.0% |
Coherus BioSciences Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $167.56 M(-4.4%) |
| Jun 2024 | - | $175.25 M(-38.3%) |
| Mar 2024 | - | $284.14 M(+9.1%) |
| Dec 2023 | $260.52 M(+136.9%) | $260.52 M(+20.3%) |
| Sep 2023 | - | $216.51 M(+53.2%) |
| Jun 2023 | - | $141.31 M(+39.3%) |
| Mar 2023 | - | $101.46 M(-7.7%) |
| Dec 2022 | $109.96 M(-10.6%) | $109.96 M(+20.6%) |
| Sep 2022 | - | $91.19 M(-21.2%) |
| Jun 2022 | - | $115.71 M(-1.1%) |
| Mar 2022 | - | $117.04 M(-4.9%) |
| Dec 2021 | $123.02 M(-21.7%) | $123.02 M(-9.8%) |
| Sep 2021 | - | $136.35 M(-3.9%) |
| Jun 2021 | - | $141.82 M(+1.0%) |
| Mar 2021 | - | $140.41 M(-10.6%) |
| Dec 2020 | $157.05 M(+10.6%) | $157.05 M(-2.3%) |
| Sep 2020 | - | $160.71 M(-6.8%) |
| Jun 2020 | - | $172.49 M(+3.0%) |
| Mar 2020 | - | $167.45 M(+17.9%) |
| Dec 2019 | $141.99 M | $141.99 M(+58.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2019 | - | $89.65 M(+15.8%) |
| Jun 2019 | - | $77.39 M(+66.5%) |
| Mar 2019 | - | $46.48 M(>+9900.0%) |
| Dec 2018 | $0.00(-100.0%) | $0.00(0.0%) |
| Sep 2017 | - | $0.00(0.0%) |
| Jun 2017 | - | $0.00(-100.0%) |
| Mar 2017 | - | $26.00 K(-98.6%) |
| Dec 2016 | $1.86 M(+19.2%) | $1.86 M(+343.7%) |
| Sep 2016 | - | $419.00 K(0.0%) |
| Jun 2016 | - | $419.00 K(-64.9%) |
| Mar 2016 | - | $1.20 M(-23.4%) |
| Dec 2015 | $1.56 M(-35.5%) | $1.56 M(+188.9%) |
| Sep 2015 | - | $540.00 K(-62.9%) |
| Jun 2015 | - | $1.45 M(-27.8%) |
| Mar 2015 | - | $2.02 M(-16.6%) |
| Dec 2014 | $2.42 M(+769.4%) | $2.42 M(>+9900.0%) |
| Sep 2014 | - | $0.00(0.0%) |
| Jun 2014 | - | $0.00(-100.0%) |
| Dec 2013 | $278.00 K(+75.9%) | $278.00 K |
| Dec 2012 | $158.00 K | - |
FAQ
- What is Coherus BioSciences annual accounts receivable?
- What is the all time high annual accounts receivable for Coherus BioSciences?
- What is Coherus BioSciences annual accounts receivable year-on-year change?
- What is Coherus BioSciences quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Coherus BioSciences?
- What is Coherus BioSciences quarterly accounts receivable year-on-year change?
What is Coherus BioSciences annual accounts receivable?
The current annual accounts receivable of CHRS is $260.52 M
What is the all time high annual accounts receivable for Coherus BioSciences?
Coherus BioSciences all-time high annual accounts receivable is $260.52 M
What is Coherus BioSciences annual accounts receivable year-on-year change?
Over the past year, CHRS annual accounts receivable has changed by +$150.56 M (+136.92%)
What is Coherus BioSciences quarterly accounts receivable?
The current quarterly accounts receivable of CHRS is $167.56 M
What is the all time high quarterly accounts receivable for Coherus BioSciences?
Coherus BioSciences all-time high quarterly accounts receivable is $284.14 M
What is Coherus BioSciences quarterly accounts receivable year-on-year change?
Over the past year, CHRS quarterly accounts receivable has changed by -$48.95 M (-22.61%)